« Back
Home /
Laduviglusib

Laduviglusib

Manufacturer	MedChem Express
Category	Oncology Neuroscience Neural Lineage Markers Aging & Neurological Disorders Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer Head & Neck Cancer Gastric Cancer Neuronal Cell Markers
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	10mM/1mL
Item no.	HY-10182-10mM
Targets	GSK-3; Wnt; β-catenin; Autophagy
CASRN	252917-06-9
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy[1][2][3].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	465.34
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer; Metabolic Disease
Solubility	DMSO : 16.67 mg/mL (ultrasonic)
Manufacturers Target	Autophagy; GSK-3; Organoid; Wnt; β-catenin
Isoform	GSK-3α; GSK-3β
Pathway	Autophagy; PI3K/Akt/mTOR; Stem Cell/Wnt
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10182-10mM-safety-datasheet.pdf